Bansal Reema, Bansal Pooja, Kulkarni Pandurang, Gupta Vishali, Sharma Aman, Gupta Amod
Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
J Ophthalmic Inflamm Infect. 2012 Mar;2(1):1-5. doi: 10.1007/s12348-011-0042-x. Epub 2011 Sep 30.
To report the behavior of intravitreal Ozurdex(®) implant in eyes with post-lensectomy-vitrectomy (PLV) aphakia.
Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex(®) for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye). Final outcome was assessed in terms of effectiveness, stability, and tolerance of the implant.
Following the implant, an initial improvement was seen in all the three eyes. However, the implant migrated into the anterior chamber (AC) at 1 week in two eyes and at 5 weeks in one eye, and wandered between the AC and vitreous cavity with changing postures of the patient. Two eyes developed corneal edema, of which one eye underwent implant removal from the AC.
Ozurdex(®) implant should be contraindicated in eyes with PLV aphakia to avoid its deleterious effect on the corneal endothelium.
报告Ozurdex（®）玻璃体内植入物在晶状体切除联合玻璃体切割术（PLV）后无晶状体眼中的表现。
回顾性分析三只PLV后无晶状体眼（三名葡萄膜炎患者），这些患者因黄斑囊样水肿（一只眼）、持续性炎症（一只眼）和低眼压（一只眼）接受了Ozurdex（®）玻璃体内注射。根据植入物的有效性、稳定性和耐受性评估最终结果。
植入后，三只眼均出现初始改善。然而，两只眼在1周时植入物迁移至前房，一只眼在5周时迁移至前房，并且随着患者姿势的改变，植入物在前房和玻璃体腔之间游动。两只眼出现角膜水肿，其中一只眼从前房取出了植入物。
PLV后无晶状体眼应禁用Ozurdex（®）植入物，以避免其对角膜内皮产生有害影响。
